Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study

Clinical trial NCT05554003 · RECRUITING

Trial details

NCT number: NCT05554003
Sponsor: European Institute of Oncology
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Neuroendocrine Tumors Frailty Chemotherapy Effect

Start date: 2022-01-14
Primary completion: 2024-12-31
Enrollment: 46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.